AI assistant
Sending…
Apimeds Pharmaceuticals US, Inc. — Director's Dealing 2025
May 20, 2025
34894_dirs_2025-05-20_e4ae747a-634c-4ac9-932e-afcaa9145572.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Apimeds Pharmaceuticals US, Inc. (APUS)
CIK: 0001894525
Period of Report: 2025-05-16
Reporting Person: Koo Jakap (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | Stock Option (right to buy) | $1.73 | A | 5780 | Acquired | 2035-05-16 | Common Stock, par value $0.01 per share (5780) | Direct |
Footnotes
F1: The option will vest in full and become exercisable on 05/16/2026.
More from Apimeds Pharmaceuticals US, Inc.
Interim / Quarterly Report
2026
May 26
Board/Management Information
2026
May 5
Annual Report
2026
May 4
Regulatory Filings
2026
May 4
Delisting Announcement
2026
Apr 22
Board/Management Information
2026
Apr 9
Major Shareholding Notification
2026
Mar 30
Regulatory Filings
2026
Mar 26
Board/Management Information
2026
Mar 25
Major Shareholding Notification
2026
Mar 20